Participants: Between April 2009 and March 2014, we
enrolled serial 57 patients with ON (27 males, 30 females; age range 16-84 years) who ophthalmologists had diagnosed as having or suspected to have ON with acute visual impairment and declined critical flicker frequency, abnormal findings of brain MRI, optical coherence tomography and fluorescein fundus angiography at their onset or recurrence. We excluded those patients who fulfilled the diagnostic criteria of neuromyelitis optica (NMO)/NMO spectrum disorders (NMOSD), MS McDonald's criteria, and so on. Finally we defined 29 patients with idiopathic ON (14 males, 15 females, age range 16-84 years).
Results: 27.6% (8/29) were positive for MOG antibodies and 3.4% (1/29) were positive for AQP4. Among the eight patients with MOG antibodies, five had optic pain (p=0.001) and three had prodromal infection (p=0.179). Three of the eight MOG-positive patients showed significantly high CSF levels of myelin basic protein (p=0.021) and none were positive for oligoclonal band in CSF. On MRIs, seven MOG-positive patients showed high signal intensity on optic nerve, three had a cerebral lesion and one had a spinal cord lesion. Seven of the eight MOGpositive patients had a good response to steroid therapy. 10 ischaemic optic neuropathies, orbital apex syndromes, Leber's hereditary optic neuropathies, tumours, trauma, thyroid-associated ophthalmopathy, pentazocine and alcohol-induced, Tolosa-Hunt syndrome, dissociated disorder and IgG4-related disease. Finally, we defined 29 patients with idiopathic ON as the study cohort (figure 1), and we retrospectively reviewed their clinical symptoms and results of their CSF examination, MRI studies and response to steroid therapies. We used ELISA for myelin basic protein (MBP) analysis, of which the cut-off level was 102 pg/mL. We prepared a standard protocol of steroid pulse therapy: methylprednisolone (mPSL) 1 g/day for three consecutive days per week for 1-5 weeks. We defined the terms to evaluate the responsiveness to steroid pulse therapies in the acute phase (before other treatments; eg, plasma exchange, fingolimod); 'complete' meant recovery to the patients' original visual acuities, 'good' meant recovery to more than half of their original visual acuities, 'not good' meant less than 'good' within 1-5 courses of mPSL pulse therapies. All of the sera samples were obtained from the patients in an acute phase at their onset or recurrence. The range of follow-up period was 3-53 months (see online supplementary table).
INTRODUCTION

Antibody assays
We transfected a full-length human MOG cDNA expression vector (kindly gifted by Prof Markus Reindl) into 293 cells of human embryonic kidney (HEK) using Lipofectamine reagent (Invitrogen Japan, Tokyo, Japan). Cell cultures were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum. Twelve hours after transfection, the HEK cells were fixed in 4% paraformaldehyde in 0.1 M phosphate-buffered saline (PBS) for 20 min. Non-specific binding was blocked with 10% goat serum/PBS; the cells were incubated with patient sera (dilution, 1:10) in 0.02% Triton X-100/10% goat serum in PBS for 1 h at room temperature followed by fluorescein isocyanate-conjugated antihuman IgG (dilution 1:50; DAKO Denmark, Glostrup, Denmark) for 1 h. SlowFade Gold antifade reagent (Invitrogen, Carlsbad, California, USA) was then applied to the slides, which were stained and observed using a fluorescence microscope (AxioVision, Carl Zeiss Microscopy, Germany).
Serum anti-AQP4 IgG antibody levels were analysed using a previously reported indirect immunofluorescence assay of HEK-293 cells transfected with an expression vector containing human AQP4 M23 cDNA. 7 The examiner (KT) of the anti-MOG and anti-AQP4 antibodies was blinded to all clinical data, including the clinical phenotype. 7 
Statistical analysis
We analysed the differences in categorical data between the group of patients with ON with MOG antibodies and the seronegative ON group using the Microsoft Excel 2010 t test, and p values <0.05 were considered to be significant.
Results
Patients
Of the 57 serial ON or suspected patients with ON, we excluded other demyelinating disorders (see figure 1) and enrolled 29 patients with idiopathic ON (14 males, 15 female, age range 16-84 years). Eight (two male, six female) of the 29 patients with ON (27.6%) were positive for MOG antibodies, and one patient was doublepositive for MOG and AQP4 (table 1) .
Demographic and clinical data
The median age of the eight MOG antibody-positive patients was 31 years, which is marginally younger than that of the patients with ON without MOG antibodies, 51 years ( p=0.052). Five of the eight patients had optic pain ( p=0.001), three had prodromal infection Two of the eight patients with MOG antibodies (25.0%) were positive for antinucleotide antibodies, compared to only three of the 18 seronegative patients with ON (16.6%). One patient had thyroid peroxidase antibodies, one had thyroid-stimulating hormone receptor antibodies and one had glomerular basement membrane antibodies; all had no neurological symptoms except for ON. All eight of the MOG antibody-positive patients were negative for oligoclonal band (OCB) in CSF, and only one seronegative ON patient was positive (5.5%, 1/18). In addition, 37.5% (3/8) of the patients with ON with MOG antibodies indicated significant positivity for MBP in CSF, as did 5.5% (1/18) of the seronegative patients with ON (p=0.021, table 1). The CSF cell count was not significantly different between the MOG-positive and MOG-negative ON groups (p=0.179).
Seven of the eight patients with ON with MOG antibodies without active underlying disease showed complete response to steroid pulse therapy. Although only one ON patient ( patient 4, online supplementary table) with MOG antibodies emerged with myelitis at her third recurrence after 12 months from onset and had received plasma exchange, no one in the seronegative ON group exhibited myelitis ( p=0.106). After her third recurrence, we prescribed fingolimod according to MS therapy, but she suffered from left optic pain and visual disturbance 19 days later, and thus we immediately stopped the fingolimod treatment. The single patient with AQP4 and MOG antibodies, who had gastric cancer, showed complete response following steroid therapy, in comparison to a previous report. 8 The median follow-up period for patients with MOG antibodies was 26.5 months (range 3-53 months), 23 months (range 3-53 months) for monophasic patients and 30 months (range 22-52 months) for relapsed patients (see online supplementary table).
MRI
All 29 idiopathic patients with ON had undergone a brain and/or spinal MRI in their acute phase. We focused on three lesions (optic nerve, cerebrum and spinal cord) and evaluated the abnormal intensities between the patients with ON with MOG antibodies and those without MOG antibodies. We found that 66.7% (14/21) of the patients without MOG antibodies showed high intensities on T2-weighted images (T2WI) in their optic nerves, as did 87.5% (7/8) of the MOG-positive patients (p=0.278). We detected high intensities in the cerebrum of 33.3% (7/21) of the MOG-negative patients and in 25.0% (2/8) of the Myelitis was not frequently observed among the present idiopathic patients with ON with MOG antibodies, compared to a previous report. 11 We suspect that the optic nerve is sensitive to MOG antibodies and that MOG antibodies cause demyelination by some immunological mechanisms, resulting in swelling and optic pain; steroid therapies might thus be effective. In the present series of patients, the swelling and high signals on MRI T2WI of optic nerves were decreased after steroid therapy. The patient with gastric cancer who was double-positive for AQP4 and MOG antibodies achieved a complete response to steroid therapy, but another patient ( patient 6, online supplementary table) who had autoimmune disease, showed no response to steroid therapy, as described previously. 8 12 Except for the above patient, the optic pain and visual acuity of our MOG-positive patients improved completely, but there was no significant difference in the clinical outcomes at the end of steroid pulse therapies between the patients with idiopathic ON with MOG antibodies and those without MOG antibodies ( p=0.870). When selecting a drug for the prevention of ON recurrence, we should deliberate and choose it based on neurological symptoms, the results of serum AQP and MOG antibody tests, and the CSF MBP level. It is possible that some immunosuppressants induce a recurrence of idiopathic ON with MOG antibodies.
CONCLUSIONS MOG is considered a target antigen in some demyelinating disorders, and MOG antibodies cause demyelination and ON, 13 similar to the pathogenesis of MS. 14 When clinicians encounter a patient with idiopathic ON, the patient's CSF, MRI, serum AQP4 antibodies and MOG antibodies, might be useful to diagnose and treat.
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